Oncology

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

A novel drug, NP137, shows unprecedented results in a Phase 1 trial, potentially making inoperable pancreatic tumors treatable and improving survival.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

The Chinese pharma giant's Q1 results reveal a successful pivot to innovation, with blockbuster deals and a strategic Nasdaq listing paving its global path.

A novel drug that targets the cellular environment of the MYC cancer protein, not the protein itself, shows major promise in preclinical studies.

A volunteer army and cutting-edge science converge this May to combat brain cancer, a disease with grim survival rates and a devastating toll on the young.

As COVID revenues fall, BioNTech bets its future on a robust oncology pipeline. The upcoming Q1 2026 report will reveal the financial health of this pivot.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.

New preclinical data for InnoCare's ICP-B794 reveals a wider safety window and power to overcome drug resistance, positioning it as a top contender.

UK biotech Promatix presented a new AI-driven platform at AACR 2026 that finds thousands of new cancer targets, promising safer, more precise 'smart bomb' drugs.

With a $30M+ boost and a public market debut, Ionetix aims to scale its cyclotron tech for cancer therapy, diagnostics, and future energy solutions.

With £21M in funding, new Focused Research Organizations, Meridial and Echo Labs, aim to tackle major bottlenecks in neuroscience and ecological intelligence.

A Northeast Georgia cancer center joins an elite national group, offering a cutting-edge 'smart bomb' therapy that brings new hope closer to home for patients.

New preclinical data reveals a T cell engager targeting multiple cancer markers at once, a novel strategy to overcome immunotherapy's limits in solid tumors.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

A Shanghai-based firm's new approach could create cancer-fighting cells inside the body, slashing costs and wait times for CAR-T therapy.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

New preclinical data reveals a novel drug, rinzimetostat, may overcome treatment resistance in prostate cancer by targeting a unique molecular switch.

New preclinical data shows SK Life Science Labs' protein degraders effectively target key drivers in prostate cancer, myeloma, and other hard-to-treat tumors.

New data reveals a novel cancer drug shrinks brain metastases in over half of small cell lung cancer patients, offering hope where options are scarce.